NEFL and amyotrophic lateral sclerosis: For example, the FDA recently granted accelerated approval to the amyotrophic lateral sclerosis therapeutic tofersen (QALSODY), based on its ability to reduce neurofilament light chain (NfL) protein levels in the blood (9).